American Century Companies Inc. Trims Position in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• American Century Companies Inc. reduced its stake in Amphastar Pharmaceuticals by 34.7%, selling 164,024 shares during the first quarter, ending with a total of 307,993 shares valued at approximately $8.9 million.
• Analysts have set varying price targets for Amphastar Pharmaceuticals, with Bank of America increasing its target from $28.00 to $32.00, while JPMorgan Chase & Co. lowered its target to $30.00.
• A significant portion, 65.09%, of Amphastar Pharmaceuticals' stock is owned by institutional investors, reflecting ongoing interest from the hedge fund community.

American Century Companies Inc. reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 34.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 307,993 shares of the company's stock after selling 164,024 shares during the period. American Century Companies Inc. owned 0.65% of Amphastar Pharmaceuticals worth $8,929,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in AMPH. GAMMA Investing LLC boosted its position in shares of Amphastar Pharmaceuticals by 4,151.3% during the 1st quarter. GAMMA Investing LLC now owns 38,644 shares of the company's stock worth $1,120,000 after purchasing an additional 37,735 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in shares of Amphastar Pharmaceuticals by 14.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company's stock valued at $400,000 after buying an additional 1,694 shares during the last quarter. Deutsche Bank AG grew its position in Amphastar Pharmaceuticals by 46.6% during the 4th quarter. Deutsche Bank AG now owns 34,082 shares of the company's stock worth $1,265,000 after purchasing an additional 10,839 shares during the last quarter. Picton Mahoney Asset Management boosted its holdings in shares of Amphastar Pharmaceuticals by 6,600.0% in the first quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company's stock valued at $46,000 after acquiring an additional 1,584 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in shares of Amphastar Pharmaceuticals by 27.2% during the 4th quarter. ProShare Advisors LLC now owns 13,852 shares of the company's stock worth $514,000 after acquiring an additional 2,958 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on AMPH shares. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, August 8th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Wells Fargo & Company decreased their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Bank of America lifted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a report on Tuesday. Finally, Needham & Company LLC upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 target price for the company in a research report on Tuesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of "Hold" and an average target price of $31.60.

Amphastar Pharmaceuticals Trading Up 1.2%

AMPH stock traded up $0.36 during mid-day trading on Friday, reaching $30.62. The company's stock had a trading volume of 290,925 shares, compared to its average volume of 638,844. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $53.96. The company has a market cap of $1.42 billion, a price-to-earnings ratio of 11.47 and a beta of 0.76. The business's 50 day moving average price is $24.60 and its 200 day moving average price is $25.79. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.